finerenone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
finerenone: clinical details
Prescribing considerations
- Check serum potassium and eGFR before initiation.
- Do not initiate when serum potassium is above the product threshold or eGFR is below 25 mL/min/1.73 m².
- Do not initiate in severe hepatic impairment; consider additional potassium monitoring in moderate hepatic impairment.
- Experience in NYHA class IV heart failure is limited.
- Review prescribed, over-the-counter and herbal products for CYP3A4 and potassium-related interactions.
- Patients with reduced renal function, previous hyperkalaemia or older age may require closer monitoring.
Contraindications and cautions
- Hypersensitivity to finerenone or an excipient
- Concomitant strong CYP3A4 inhibitor treatment
- Addison’s disease
Monitoring
- Serum potassium and eGFR before treatment.
- Repeat potassium and eGFR after initiation, restarting or a treatment change, then periodically according to clinical risk.
- Monitor renal function more frequently in older adults and those with impaired renal function.
- Monitor blood pressure when used with several antihypertensive agents.
- Consider additional potassium monitoring with CYP3A4 inhibitors, potassium supplements or trimethoprim-containing treatment.
Clinical pharmacology
Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist. It is rapidly absorbed, highly protein-bound and metabolised predominantly by CYP3A4, with a smaller CYP2C8 contribution. Its circulating metabolites are inactive, and its plasma elimination half-life is approximately two to three hours.
Formulation and product differences
- The selected presentation is a film-coated tablet containing lactose and is essentially sodium-free.
- Tablets can be crushed and mixed with water or soft food immediately before administration.
- Tablet appearance varies between marketed strengths; consult the relevant product information for identification.
finerenone preparations and strengths
Tablet
Route: Oral
Strengths: 10 mg, 20 mg, 40 mg
finerenone interactions
A complete medicines review is important because finerenone is mainly metabolised by CYP3A4 and can raise potassium.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, ketoconazole, ritonavir and cobicistat
Contraindicated because they can markedly increase finerenone exposure.
Rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz and St John’s wort
Avoid because CYP3A4 induction can reduce finerenone exposure and effectiveness.
Spironolactone, eplerenone and other mineralocorticoid receptor antagonists
Do not combine because the risk of high potassium increases.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.